Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyAnthem IVIG/SCIG Coverage & Prior Auth Update | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    ModifiedAnthemPolicy CC-0003

    Immunoglobulins (IVIG/SCIG) — Coverage Criteria and Prior Authorization

    Customize your policy alerts

    Sign up for Anthem Policy CC-0003 alerts

    Get alerted when Policy CC-0003 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical policy governing use of intravenous and subcutaneous immunoglobulin products for medical indications; applies to Anthem medical benefit reviews and prior authorization decisions.

    Policy Summary
    PayerAnthem
    PolicyImmunoglobulins (IVIG/SCIG) — Coverage Criteria and Prior Authorization
    Policy CodePolicy CC-0003
    Change TypeCoding, step therapy, product list and clinical criteria updates
    Effective DateMar 26, 2026
    Last ReviewMar 26, 2026
    Next Review DateMar 26, 2026
    Key ActionObtain prior authorization with clinical documentation showing the specific indication and meeting listed clinical and laboratory criteria.
    SourceLink
    POLICY UPDATE CHANGES

    Step therapy table updates and coding updates including removal of Yimmugo from HCPCS NOC C9399 and J3590 effective 3/31/26 and addition of J1553 effective 4/1/26; added J1599 for Qivigy and other code adjustments.

    Added new HCPCS codes and product entries (e.g., J1576, J1572, J1599, J1553, J1569, Q2052) and added products Qivigy and Gammagard Liquid ERC to clinical criteria and step therapy properties.

    Updated clinical criteria for CIDP and multiple myeloma and added indications including immune checkpoint inhibitor-related toxicities and warm-type autoimmune hemolytic anemia.

    Preferred and non-preferred lists of IVIG/SCIG products were updated with effective dates 02/01/2025 and 05/01/2026 (Commercial) and 04/01/2025 and 05/01/2026 (Medicare).

    Gammagard Liquid ERC was added to the Commercial preferred agents list effective 05/01/2026.

    Qivigy was added to the Commercial non-preferred intravenous agents list effective 05/01/2026.

    IV & SCroutes addressed
    ~30HCPCS codes listed
    Non-preferred requires trialsstep therapy required
    1 yearcontinuation duration
    Thrombosis/Renalblack box warnings
    <500 mg/dLIgG threshold example

    Coverage Criteria and Clinical Requirements

    General medical necessity framework

    Covered when ALL of the following are met per medical review/prior authorization:

    General: Use of IVIG or SCIG is reviewed under the member's medical benefit and must meet the policy's clinical criteria for the intended/prescribed purpose.

    See specific indication sections in subsequent document parts for detailed criteria.

    CIDP diagnostic criteria

    Diagnosis-specific requirements (example: CIDP)

    CIDP diagnostic electrodiagnostic criteria: At least one of specified demyelinating parameters per EFNS/PNS or at least three of four AAN demyelinating parameters are required to confirm CIDP, and symptom duration >2 months.symptom duration >2 months; see EFNS/PNS and AAN numeric thresholds in policy (e.g., % prolongation, conduction velocity reductions, F-wave criteria).

    Electrodiagnostic findings (NCS/EMG) must be documented in the record.

    Policy Summary
    PayerAnthem
    PolicyImmunoglobulins (IVIG/SCIG) — Coverage Criteria and Prior Authorization
    Policy CodePolicy CC-0003
    Change TypeCoding, step therapy, product list and clinical criteria updates
    Effective DateMar 26, 2026
    Last ReviewMar 26, 2026
    Next Review DateMar 26, 2026
    Key ActionObtain prior authorization with clinical documentation showing the specific indication and meeting listed clinical and laboratory criteria.
    SourceLink
    On This Page
    Coverage Criteria and Clinical RequirementsBilling and Code ListingsPrior Authorization, Documentation, and Step TherapyBackground and ScopeDefinitions and Key TermsDocument History and Policy Changes

    Primary immunodeficiency

    Covered when ALL of the following are met for specified primary humoral immunodeficiencies:

    Primary humoral immunodeficiency specific criteria: Initial pre-treatment total serum IgG is below the lower limit of the age‑adjusted laboratory reference range or >2 standard deviations below the age‑adjusted mean; AND there is no evidence that renal (e.g., nephrotic syndrome) or gastrointestinal (e.g., protein‑losing enteropathy) causes of hypogammaglobulinemia are present.IgG below age‑adjusted reference or >2 SD below mean

    Applies to congenital agammaglobulinemia, X‑linked agammaglobulinemia, Wiskott‑Aldrich syndrome and similar primary humoral PIs per AAAAI/ACAAI guidance.

    Common variable immunodeficiency (CVID)

    Covered when ALL of the following are met:

    CVID criteria: History of recurrent sinopulmonary infections requiring antibiotic therapy consistent with common variable immunodeficiency (CVID).

    Documentation of infection history required (per AAAAI/ACAAI 2015).

    Secondary immunodeficiencies

    Covered for specified secondary causes when criteria are met:

    Included secondary immunodeficiencies: Includes conditions such as: B‑cell chronic lymphocytic leukemia (CLL) with recurrent/active bacterial infections and total IgG <500 mg/dL; multiple myeloma with clinically severe infection or functional IgG <400 mg/dL; HIV‑infected children with IgG <400 mg/dL or recurrent infections; IgG subclass deficiency or specific antibody deficiency with recurrent infections and inadequate vaccine response.IgG thresholds specified per condition (e.g., CLL <500 mg/dL; functional IgG <400 mg/dL for multiple myeloma; HIV pediatric threshold <400 mg/dL).

    Documentation of recurrent infections, vaccine response testing, and measured IgG or subclass values required (references: NCCN, IDSA/CDC).

    Transplant-related indications

    Covered when ALL of the following for transplant contexts are met:

    HCT and solid organ transplant indications: Includes: (1) Allogeneic bone marrow transplant recipients in the first 100 days after transplant for reduction of risk of interstitial pneumonia and infections; OR (2) prevention of bacterial infections after allogeneic HCT when severe hypogammaglobulinemia (IgG <400 mg/dL) is present; OR (3) solid organ transplant desensitization or management of antibody‑mediated rejection for individuals with high PRA/cPRA or donor‑specific antibodies, or transplant recipients at increased CMV risk.First 100 days post‑allogeneic BMT for some indications; IgG <400 mg/dL for prevention of bacterial infection after HCT.

    References include ASBMT, KDIGO, ISHLT guidance as cited in policy.

    Autoimmune encephalitis (AE)

    Covered when ALL of the following are met:

    Autoimmune encephalitis (AE) initial criteria: Evaluation for possible neoplasm completed; diagnosis confirmed (detection of a specific autoantibody associated with AE, e.g., NMDAR, LGI1, Caspr2, AMPAR, GABA receptors, IgLON5, DPPX, GlyR, mGluR antibodies); clinical presentation includes neurologic features and alternative infectious/other etiologies have been ruled out.Initial trial up to 12 weeks; continuation requests require clinical improvement and ongoing cancer screening.

    Continued use requires demonstrated clinically significant improvement and continued need; see policy for antibody list and continuation criteria.

    Immune checkpoint inhibitor-related toxicities

    Covered when ALL of the following are met:

    Immune checkpoint inhibitor (ICI)-related toxicity criteria: The offending ICI has been interrupted or discontinued; the individual has had a trial and inadequate response or intolerance to corticosteroids; AND the individual has one of the specified severe ICI‑related toxicities (examples: myocarditis; severe or life‑threatening bullous dermatitis; SJS/TEN; hemolytic anemia; severe aplastic anemia; thrombocytopenia; severe or life‑threatening myositis; severe or progressing encephalitis; demyelinating disease such as optic neuritis or transverse myelitis; severe pneumonitis).

    NCCN 2A referenced — document clinical details and prior steroid trial in record.

    Other autoimmune/hematologic indications

    Covered when specific condition-level criteria are met:

    Other autoimmune and hematologic indications: Examples include: parvovirus B19 chronic infection with severe anemia associated with marrow suppression; isoimmune hemolytic disease of the newborn for severe hyperbilirubinemia; warm autoimmune hemolytic anemia after failed/intolerant trials of steroids and another agent and transfusion dependence; autoimmune mucocutaneous blistering diseases after inadequate response/intolerance to standard therapies.

    Condition‑specific references and trial requirements vary (see policy for details, e.g., ACOG, AAAAI guidance).

    Dermatomyositis / Polymyositis

    Covered when ALL of the following are met:

    Dermatomyositis/Polymyositis initial criteria: Inadequate response to, intolerance of, or contraindication to corticosteroids and other immunosuppressive agents; diagnosis supported by at least four of eight characteristic features (for example: proximal weakness, elevated CK/aldolase, EMG/NCS findings, myositis‑specific antibodies, characteristic skin findings for dermatomyositis); if dermatomyositis, characteristic skin lesions must be present.

    Initial approval typically 6 months; continuation requires clinically significant improvement and continued need.

    Neurologic disorders (selected)

    Covered when condition-specific criteria are met:

    Selected neurologic disorders (examples): Lambert‑Eaton myasthenic syndrome: muscle weakness with diagnostic confirmation by electrodiagnostics or VGCC antibodies; initial approval 12 weeks and continuation requires objective improvement. Guillain‑Barré Syndrome (GBS): characteristic presentation with progressive weakness and areflexia, IVIG initiated within 8 weeks of symptom onset, not concurrently on plasmapheresis, treatment limited to one course (≤5 days).GBS: initiation within 8 weeks of onset; treatment ≤5 days. Lambert‑Eaton initial 12 weeks then continuation 1 year.

    Objective electrodiagnostic testing and documentation of timing/symptom onset required.

    Dermatomyositis or Polymyositis

    Covered when the following are met:

    Dermatomyositis/Polymyositis approval durations: Initial approval for dermatomyositis or polymyositis is up to 6 months; continuation approvals up to 1 year when clinical benefit and continued need are demonstrated (positive response/stability on dose or relapse on dose reduction).

    See policy for required diagnostic features and documentation of response.

    Guillain-Barré Syndrome (GBS)

    Covered when ALL of the following are met:

    GBS initial treatment: Clinical presentation characteristic of Guillain‑Barré Syndrome (progressive limb weakness and absent/depressed tendon reflexes); initial IVIG treatment initiated within 8 weeks of symptom onset; not on concomitant plasmapheresis; treatment limited to one course (no more than 5 days).Initiation within 8 weeks; treatment ≤5 days

    Documentation of symptom onset date and exclusion of concurrent plasmapheresis required.

    Myasthenia Gravis

    Initial and continuation use when criteria are met:

    Myasthenia Gravis — initial criteria: Clinical presentation consistent with myasthenia gravis AND diagnosis confirmed by acetylcholine receptor (AchR) or MuSK antibodies OR characteristic electrodiagnostic findings (RNS or SFEMG); and use is for exacerbation/crisis, short‑term bridging while immunosuppressants take effect, or maintenance when intolerant/inadequate response/contraindication to pyridostigmine, corticosteroids, and non‑steroidal immunosuppressants (required trial durations specified in policy).See policy for required trial durations (e.g., 12 months for azathioprine/mycophenolate; 2 months for certain alternate agents).

    Continuation requires clinically significant objective improvement and demonstrated continued need.

    Myasthenia Gravis — continuation criteria: Clinically significant and objective improvement on neurological exam AND continued need demonstrated by clinical effect (stable on current dose or worsening with dose decrease/interval increase).

    Continuation approvals typically 1 year.

    Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    Covered as initial trial and for continued use when criteria met:

    CIDP — initial criteria: Diagnosis verified by clinical presentation consistent with typical or atypical CIDP (progressive/stepwise/recurrent symmetric proximal and distal weakness and sensory dysfunction developing over ≥2 months with absent or reduced reflexes) AND objective functional impairment (for example needing support to walk or upper limb deficits affecting daily tasks).Symptom duration ≥2 months

    Initial trial up to 12 weeks.

    CIDP — continuation criteria: Clinically significant improvement on exam AND continued need demonstrated by clinical effect (positive response and stability on current dose or worsening with dose decrease/interval increase).

    Continuation approval typically 1 year.

    Multifocal Motor Neuropathy (MMN)

    Covered as initial trial and for continuation when criteria are met:

    MMN — initial criteria: Stepwise or slowly progressive focal asymmetric limb weakness ≥1 month; motor involvement of ≥2 nerves; normal sensory nerve conduction studies except minor vibration loss; absence of upper motor neuron signs (unless explained by comorbidity); characteristic electrodiagnostic findings in ≥1 nerve; other causes of neuropathy ruled out.Symptom duration ≥1 month

    Initial trial up to 12 weeks; continuation approval typically 1 year.

    Stiff-Person Syndrome

    Covered when ALL of the following are met:

    Stiff‑Person Syndrome (SPS) criteria: Inadequate response to, intolerance of, or contraindication to other standard treatments (for example benzodiazepines or baclofen) for initial requests; continued use requires clinically significant objective improvement and demonstrated continued need.

    Initial approval generally 12 weeks; continuation 1 year.

    MOG-related NMOSD

    Covered for induction and maintenance when criteria are met:

    MOG‑related NMOSD — initial criteria: Individual is seropositive for MOG antibodies and seronegative for AQP4 antibodies; IVIG is used as induction for an acute episode after inadequate response/intolerance/contraindication to corticosteroids OR for relapse after maintenance therapy with corticosteroids and non‑steroidal immunosuppressants.

    Initial approval typically 6 months; continuation approvals up to 1 year with documented clinical response (e.g., reduced relapse frequency).

    MOG‑related NMOSD — continuation criteria: Continued maintenance use when the individual has experienced a clinical response to immune globulin (for example, reduced relapse frequency).

    Continuation approval typically 1 year.

    Miscellaneous Indications and Post-exposure Prophylaxis

    Covered for specific infectious and other acute conditions when criteria are met:

    Measles (rubeola) post‑exposure prophylaxis: Administered within 6 days of exposure and not given concomitantly with a measles‑containing vaccine; used for nonimmune individuals at risk for severe disease (for example pregnant women, severely immunocompromised).Within 6 days of exposure

    Vaccination may be given ≥8 months after IG administration per guidance.

    Varicella post‑exposure prophylaxis: Used for susceptible individuals when varicella‑zoster immune globulin (VZIG) is unavailable.

    Policy cites AHFS guidance.

    Tetanus treatment or PEP: Used when tetanus immune globulin (TIG) is unavailable.

    Policy cites AHFS guidance.

    Kawasaki syndrome: Treatment initiated within 10 days of onset OR beyond 10 days if unexplained persistent fever or coronary artery abnormalities with ongoing inflammation; treatment for no more than 5 days.Within 10 days of onset (or specific exceptions)

    Approval durations and timing per AHA guidance.

    Toxic shock syndrome: Used for toxic shock syndrome caused by staphylococcal or streptococcal organisms.

    Policy cites AAP/AHFS guidance.

    Cancer‑related CMV pneumonia: Treatment when individual has hypogammaglobulinemia (IgG <500 mg/dL).IgG <500 mg/dL

    Approval duration typically 6 months per NCCN guidance.

    Non-preferred IVIG

    Non-preferred Intravenous Immunoglobulins (IVIG) — approval when ONE of the following is met

    Non‑preferred IVIG approval criteria: I. Documentation of trial and inadequate response or intolerance to two preferred IVIG agents; OR II. Documentation that preferred IVIG agents are not acceptable due to concomitant clinical condition(s) requiring an IG agent with specific properties (examples: severe IgA deficiency <7 mg/dL or IgA deficiency with antibodies to IgA; hypersensitivity/anaphylaxis to an ingredient not present in requested agent; clinically significant reaction such as hemolysis or renal dysfunction that may be lessened by non‑preferred agent); OR III. Preferred agents are not FDA‑approved and do not have accepted off‑label use for the indication and the requested non‑preferred agent does.

    Documentation of prior trials or clinical rationale required per step therapy rules.

    SCIG-only Step Therapy

    Subcutaneous Immunoglobulins (SCIG)-only Step Therapy — approval when specified criteria met

    Preferred SCIG‑only approval: I. Documentation of trial and inadequate response or intolerance to IVIG due to listed reasons (for example, serious systemic reaction to IVIG expected to be avoided by SCIG; inconsistent serum IgG levels with IVIG); OR II. Documentation of difficult venous access AND rationale why Gamunex‑C cannot be administered subcutaneously.

    A list of preferred SCIG agents is maintained; documentation required.

    Non‑preferred SCIG‑only approval: I. Documentation of trial and inadequate response or intolerance to two preferred SCIG agents; OR II. Documentation that preferred SCIG‑only agent is not acceptable due to concomitant clinical condition(s) (examples: severe IgA deficiency <7 mg/dL or IgA antibodies to IgA; hypersensitivity to ingredient not present in requested agent; clinically significant reaction such as hemolysis or renal dysfunction); OR III. Preferred SCIG agents are not FDA‑approved and do not have accepted off‑label use for the prescribed indication.

    Documentation of trials and rationale required; policy lists examples of acceptable clinical reasons.

    Quantity Limits

    Intravenous Immunoglobulin Quantity Limits — dosing per indication

    Quantity limits by indication: Per‑indication dosing limits are specified (examples): CIDP: 1000 mg/kg (may be divided over two days) as frequently as every 3 weeks (loading up to 2000 mg/kg allowed on initiation); CLL: 500 mg/kg monthly; Dermatomyositis: 2000 mg/kg divided over 2–5 days every 4 weeks; Guillain‑Barré: 400 mg/kg daily ×5 days or 2000 mg/kg divided over 2–5 days; ITP: 2000 mg/kg divided over 2–5 days or 1000 mg/kg every other day up to 3 doses; Kawasaki: 2000 mg/kg per dose up to two doses (or 400 mg/kg/day ×4 days); MMN: 2400 mg/kg every 4 weeks (may be every 2 weeks based on response); Myasthenia Gravis: 2000 mg/kg divided over 2–5 days; Primary immunodeficiencies: 800 mg/kg q3 weeks (higher doses may be approved per physician rationale).Dose and frequency limits per indication as listed

    Override criteria for CIDP initiation may allow loading doses up to 2000 mg/kg in divided doses over 2–5 days.

    Clinical criteria (excerpted)

    Policy includes multiple indication-specific criteria and step therapy requirements; detailed criteria per indication are in other parts of the policy.

    Criteria summary placeholder: Indication‑specific medical necessity and continuation criteria (e.g., CIDP, myasthenia gravis, primary immunodeficiency, ITP, MMN, GBS, AE, transplant‑related uses) have been updated across document history; see full policy for exact nested AND/OR logic and laboratory thresholds.see full policy

    This excerpt documents updates and coding/step therapy changes but does not include the full nested criteria for every indication.

    Commercial preferred/non-preferred lists

    Product preference lists for Commercial Medical Benefit by effective date

    Commercial preferred — 02/01/2025: Preferred Agents (02/01/2025) — Intravenous: Gamunex‑C, Octagam; Subcutaneous: Cutaquig, Hizentra, Xembify.

    Some products (e.g., Gamunex‑C) may be administered IV or SC.

    Commercial non‑preferred — 02/01/2025: Non‑Preferred Agents (02/01/2025) — Intravenous and Subcutaneous lists as specified in policy (examples include Alyglo, Asceniv, Bivigam, Flebogamma DIF, Gammaked, Gammagard, Gammaplex, Panzyga, Privigen, Yimmugo; Cuvitru, HyQvia for SC).

    See policy for the complete product lists and mapping to HCPCS codes.

    Commercial preferred — 05/01/2026: Preferred Agents (05/01/2026) — Intravenous: Gamunex‑C, Octagam; Subcutaneous: Cutaquig, Hizentra, Xembify, Gammagard Liquid ERC.

    Subcutaneous preferred products require step through an intravenous product per policy.

    Commercial non‑preferred — 05/01/2026: Non‑Preferred Agents (05/01/2026) — Includes Subcutaneous: Cuvitru, HyQvia; Intravenous: Alyglo, Asceniv, Bivigam, Flebogamma DIF, Gammaked, Gammagard, Gammagard Liquid ERC, Gammagard S/D, Gammaplex, Panzyga, Privigen, Qivigy, Yimmugo.

    Preferred/non‑preferred status and effective dates are maintained in the policy.

    Medicare preferred/non-preferred lists

    Product preference lists for Medicare Medical Benefit by effective date

    Medicare preferred — 04/01/2025: Preferred Agents (04/01/2025) — Intravenous: Gamunex‑C, Octagam; Subcutaneous: Cutaquig, Hizentra.

    Some agents may be administered IV or SC.

    Medicare non‑preferred — 04/01/2025: Non‑Preferred Agents (04/01/2025) — Intravenous and Subcutaneous lists as specified (examples include Alyglo, Asceniv, Bivigam, Flebogamma DIF, Gammaked, Gammagard, Gammagard S/D, Gammaplex, Panzyga, Privigen, Yimmugo; Cuvitru, HyQvia for SC).

    See policy for full product mappings and coding.

    Medicare preferred — 05/01/2026: Preferred Agents (05/01/2026) — Intravenous: Gamunex‑C, Octagam; Subcutaneous: Cutaquig, Hizentra, Xembify.

    Subcutaneous preferred products require step through IV product per policy.

    Medicare non‑preferred — 05/01/2026: Non‑Preferred Agents (05/01/2026) — Includes Cuvitru, HyQvia; Intravenous: Alyglo, Asceniv, Bivigam, Flebogamma DIF, Gammaked, Gammagard, Gammagard Liquid ERC, Gammagard S/D, Gammaplex, Panzyga, Privigen, Qivigy, Yimmugo.

    Preferred/non‑preferred lists and effective dates captured from policy.

    This policy covers intravenous (IVIG) and subcutaneous (SCIG) immunoglobulin products but does not address use of GamaSTAN or GamaSTAN S/D. It also excludes Rho (D) immune globulin and WinRho SD for prevention or treatment of Rh incompatibility; those products and indications are handled separately. Providers should use the HCPCS/J-code listings and product-specific guidance in the coding section when submitting requests for IVIG/SCIG products that are within the policy scope.

    Requests for immunoglobulin therapy are implicitly excluded when the required diagnostic, laboratory, or prior‑therapy criteria for the intended indication are not documented. Examples include absence of pre‑treatment total serum IgG below age‑adjusted reference when required for primary humoral immunodeficiency, lack of documented recurrent infections or inadequate vaccine response where those are specified, or failure to document trials and inadequate response/intolerance to preferred therapies for autoimmune/neurologic indications. Such missing documentation is a basis for denial under the policy.

    The policy expressly lists conditions for which immunoglobulin therapy is not approved. These include treatment of Alzheimer's disease, immune optic neuropathy except for MOG‑related NMOSD, multiple sclerosis, PANDAS/PANS, treatment to prevent recurrent spontaneous abortion, and other indications that do not meet the listed clinical criteria. Requests for these indications should be considered not medically necessary.

    Anthem maintains lists of preferred and non‑preferred IVIG and SCIG agents by benefit and effective date. When clinical criteria are met, benefit plans may still require use of a preferred agent first. Requests for a non‑preferred product must include documentation of trials and inadequate response or intolerance to two preferred agents, or a clear clinical rationale (for example, severe IgA deficiency <7 mg/dL, hypersensitivity to an excipient, or other specified exceptions). Absence of required trials or acceptable clinical rationale may result in denial of coverage for non‑preferred products.

    Billing and Code Listings

    IG products and propertiesmixed
    Agent listListing of IG products and selected properties (e.g., Alyglo 10% IV, Asceniv 10% IV, Bivigam 10% IV, Cutaquig 16.5% SC, etc.)
    IG products and properties - source notemixed
    SourceSee policy product/property table for full product list and selected properties.
    Covered CPT Codes (administration)CPT
    90283Immune globulin, (IgIV), human, for intravenous use, 100 mg
    90284Immune globulin, (SCIg), human, for use in subcutaneous infusions, 100 mg
    HCPCS/J-codesHCPCS
    C9399Unclassified drugs or biologicals (when specified as Qivigy or other IG products)
    J1459Injection, immune globulin (Privigen), intravenous, non-lyophilized, 500 mg
    J1551Injection, immune globulin (Cutaquig), 100 mg
    J1552Injection, immune globulin (Alyglo), 500 mg
    J1553Injection, immune globulin (Yimmugo), 100 mg
    J1554Injection, immune globulin (Asceniv), 500 mg
    J1555Injection, immune globulin (Cuvitru), 100 mg
    J1556Injection, immune globulin (Bivigam), 500 mg
    HCPCS - UnclassifiedHCPCS
    C9399Unclassified drugs or biologicals [when specified as Qivigy (immune globulin intravenous, human-kthm)]
    HCPCS - Product-specific (group 1)HCPCS
    J1459Injection, immune globulin (Privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1551Injection, immune globulin (Cutaquig), 100 mg
    J1552Injection, immune globulin (Alyglo), 500 mg
    J1553Injection, immune globulin (Yimmugo), 100 mg
    HCPCS - Product-specific (group 2)HCPCS
    J1554Injection, immune globulin (Asceniv), 500 mg
    J1555Injection, immune globulin (Cuvitru), 100 mg
    J1556Injection, immune globulin (Bivigam), 500 mg
    HCPCS - Product-specific (group 3)HCPCS
    J1557Injection, immune globulin (Gammaplex), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1558Injection, immune globulin (Xembify), 100 mg
    J1559Injection, immune globulin (Hizentra), 100 mg
    HCPCS - Product-specific (group 4)HCPCS
    J1561Injection, immune globulin (Gamunex-C/Gammaked), non-lyophilized (e.g., liquid), 500 mg
    J1566Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg [Carimune NF, Gammagard S/D]
    HCPCS - Product-specific (group 5)HCPCS
    J1568Injection, immune globulin (Octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1569Injection, immune globulin (Gammagard Liquid), non-lyophilized (e.g., liquid), 500 mg
    Listed HCPCS J-codes for common IV and SC immune globulinsHCPCS
    J1558Injection, immune globulin (Xembify), 100 mg
    J1559Injection, immune globulin (Hizentra), 100 mg
    J1561Injection, immune globulin, (Gamunex-C/Gammaked), non-lyophilized (e.g., liquid), 500 mg
    J1566Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg [Carimune NF, Gammagard S/D]
    J1568Injection, immune globulin, (Octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1569Injection, immune globulin, (Gammagard Liquid), non-lyophilized (e.g., liquid), 500 mg [Gammagard Liquid, Gammagard Liquid ERC]
    Additional HCPCS J-codes in listHCPCS
    J1572Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1575Injection, immune globulin/hyaluronidase, (HyQvia), 100 mg immune globulin
    Listed HCPCS Immunoglobulin CodesHCPCS
    J1559Injection, immune globulin (Hizentra), 100 mg
    J1561Injection, immune globulin, (Gamunex-C/Gammaked), non-lyophilized (e.g., liquid), 500 mg
    J1566Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg [Carimune NF, Gammagard S/D]
    J1568Injection, immune globulin, (Octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1569Injection, immune globulin, (Gammagard Liquid), non-lyophilized (e.g., liquid), 500 mg [Gammagard Liquid, Gammagard Liquid ERC]
    J1572Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lypohilizied (e.g., liquid), 500 mg
    J1575Injection, immune globulin/hyaluronidase, (HyQvia), 100 mg immune globulin
    J1576Injection, immune globulin (Panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg
    Covered HCPCS Codes (listed in excerpt)HCPCSCovered
    J1561Injection, immune globulin, (Gamunex-C/Gammaked), non-lyophilized (e.g., liquid), 500 mg
    J1566Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg [Carimune NF, Gammagard S/D]
    J1568Injection, immune globulin, (Octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1569Injection, immune globulin, (Gammagard Liquid), non-lyophilized (e.g., liquid), 500 mg [Gammagard Liquid, Gammagard Liquid ERC]
    J1572Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lypohilizied (e.g., liquid), 500 mg
    J1575Injection, immune globulin/hyaluronidase, (HyQvia), 100 mg immune globulin
    J1576Injection, immune globulin (Panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1599Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified
    HCPCS codes for immunoglobulin productsHCPCS
    J1561Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1566Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg [Carimune NF, Gammagard S/D]
    J1568Injection, immune globulin, (Octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1569Injection, immune globulin, (Gammagard Liquid), non-lyophilized (e.g., liquid), 500 mg [Gammagard Liquid, Gammagard Liquid ERC]
    J1572Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lypohilizied (e.g., liquid), 500 mg
    J1575Injection, immune globulin/hyaluronidase, (HyQvia), 100 mg immune globulin
    J1576Injection, immune globulin (Panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1599Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg [when specified as Qivigy (immune globulin intravenous, human-kthm)]
    J3590Unclassified biologics [when specified as Qivigy (immune globulin intravenous, human-kthm)]
    Listed HCPCS Immune Globulin CodesHCPCS
    J1566Injection, immune globulin, intravenous, lyophilized (e.g., powder), not otherwise specified, 500 mg [Carimune NF, Gammagard S/D]
    J1568Injection, immune globulin, (Octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1569Injection, immune globulin, (Gammagard Liquid), non-lyophilized (e.g., liquid), 500 mg [Gammagard Liquid, Gammagard Liquid ERC]
    J1572Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lypohilizied (e.g., liquid), 500 mg
    J1575Injection, immune globulin/hyaluronidase, (HyQvia), 100 mg immune globulin
    J1576Injection, immune globulin (Panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1599Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg [when specified as Qivigy (immune globulin intravenous, human-kthm)]
    J3590Unclassified biologics [when specified as Qivigy (immune globulin intravenous, human-kthm)]
    Home infusion supply/service codeHCPCS
    Q2052Services, supplies and accessories used in the home for the administration of intravenous.
    Covered HCPCS/J-codes for immune globulins and home suppliesHCPCSCovered
    J1566Injection, immune globulin, 500 mg [Carimune NF, Gammagard S/D]
    J1568Injection, immune globulin (Octagam), intravenous, non-lyophilized, 500 mg
    J1569Injection, immune globulin (Gammagard Liquid), non-lyophilized, 500 mg [Gammagard Liquid, Gammagard Liquid ERC]
    J1572Injection, immune globulin (Flebogamma/Flebogamma DIF), intravenous, non-lyophilized, 500 mg
    J1575Injection, immune globulin/hyaluronidase (HyQvia), 100 mg immune globulin
    J1576Injection, immune globulin (Panzyga), intravenous, non-lyophilized, 500 mg
    J1599Injection, immune globulin, intravenous, non-lyophilized, not otherwise specified, 500 mg [when specified as Qivigy]
    J3590Unclassified biologics [when specified as Qivigy (immune globulin intravenous, human-kthm)]
    Q2052Services, supplies and accessories used in the home for the administration of intravenous immune globulin (IVIG)
    HCPCS/J-codes and S/Q codes for IVIG/SCIG and home infusionHCPCS
    J1566500 mg [Carimune NF, Gammagard S/D]
    J1568Injection, immune globulin, (Octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1569Injection, immune globulin, (Gammagard Liquid), non-lyophilized (e.g., liquid), 500 mg
    J1572Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1575Injection, immune globulin/hyaluronidase, (HyQvia), 100 mg immune globulin
    J1576Injection, immune globulin (Panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1599Injection, immune globulin, intravenous, non-lyophilized (e.g., liquid), not otherwise specified, 500 mg [when specified as Qivigy (immune globulin intravenous, human-kthm)]
    J3590Unclassified biologics [when specified as Qivigy (immune globulin intravenous, human-kthm)]
    Q2052Services, supplies and accessories used in the home for the administration of intravenous immune globulin (IVIG)
    S9338Home infusion therapy; immunotherapy, administrative services, professional pharmacy services, care coordination, all necessary supplies and equipment, per diem
    Covered HCPCS/J/Q/S CodesHCPCSCovered
    J1568Injection, immune globulin, (Octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg
    J1569Injection, immune globulin, (Gammagard Liquid), non-lyophilized (e.g., liquid), 500 mg [Gammagard Liquid, Gammagard Liquid ERC]
    J1572Injection, immune globulin, (Flebogamma/Flebogamma DIF), intravenous, non-lypohilizied (e.g., liquid), 500 mg
    J1575Injection, immune globulin, (HyQvia), 100 mg immune globulin
    J1576Injection, immune globulin (Panzyga), 500 mg
    J1599Injection, immune globulin, intravenous, non-lyophilized, not otherwise specified, 500 mg [when specified as Qivigy (immune globulin intravenous, human-kthm)]
    J3590Unclassified biologics [when specified as Qivigy (immune globulin intravenous, human-kthm)]
    Q2052Services, supplies and accessories used in the home for the administration of intravenous immune globulin (IVIG)
    S9338Home infusion therapy; immunotherapy, administrative services, professional pharmacy, care coordination; per diem
    Diagnosis codesICD-10
    ICD-10All diagnoses
    HCPCS codes mentionedHCPCS
    J1575Injection, immune globulin/hyaluronidase, (HyQvia), 100 mg immune globulin
    J1576Injection, immune globulin (Panzyga), intravenous, non-lyophilized, 500 mg
    J1599Injection, immune globulin, intravenous, non-lyophilized, not otherwise specified, 500 mg [when specified as Qivigy]
    J3590Unclassified biologics [when specified as Qivigy]
    J1553HCPCS code added per document history (see history for product mapping)
    C9399HCPCS NOC (used historically for certain products like Yimmugo or Gammagard Liquid ERC as noted in history)
    Q2052Services, supplies and accessories used in the home for the administration of intravenous immune globulin (IVIG)
    S9338Home infusion therapy; immunotherapy, administrative services, professional pharmacy, per diem
    ICD-10 scopeICD-10
    All diagnosesPolicy notes 'All diagnoses' under ICD-10 Diagnosis section
    No billing codes listed in this sectionmixed
    No codes listed
    inv-65: CIDP symptom duration — key clinical threshold
    CIDP symptom durationSymptom duration greater than 2 months (≥8 weeks) to distinguish CIDP from acute inflammatory demyelinating polyradiculoneuropathy (AIDP).
    Electrodiagnostic confirmation requirementElectrodiagnostic findings per EFNS/PNS or AAN criteria must be documented (see demyelinating parameter thresholds).
    Initial approval contextInitial CIDP treatment courses typically authorized as a trial (initial requests up to 12 weeks) with continuation based on objective improvement.
    inv-66: Total serum IgG — lab threshold guidance and references
    Total serum IgG threshold (primary PID)Initial pre-treatment total serum IgG below the lower limit of the age‑adjusted laboratory reference range or >2 standard deviations below the age‑adjusted mean.
    CLL-specific thresholdTotal IgG less than 500 mg/dL for B-cell chronic lymphocytic leukemia with recurrent/active infection.
    HCT / transplant thresholdSome transplant indications reference IgG less than 400 mg/dL for severe hypogammaglobulinemia after allogeneic HCT.
    inv-67: Functional IgG (multiple myeloma) — specific numeric threshold
    Functional IgG threshold (multiple myeloma)Functional (polyclonal) IgG less than 400 mg/dL — estimate by subtracting the M spike from total IgG.
    Context of useApplies when multiple myeloma patient has clinically severe or active infection per NCCN 2A guidance.
    Estimation notePolyclonal functional IgG may be approximated by total IgG minus monoclonal M spike value.
    inv-68: CD3+ T cell count (SCID) — numeric threshold for SCID
    CD3+ T cell count threshold (SCID)CD3+ T cell count less than 300 cells/mm3 is a criterion for severe combined immunodeficiency (SCID).
    Alternate SCID criterionPresence of maternal T cells in the circulation is an alternative qualifying finding to low CD3+ count.
    Associated IgG requirementEither low total serum IgG (below age‑adjusted lower limit) or CD3+ <300 cells/mm3 satisfies SCID laboratory criterion when other causes excluded.
    inv-69: GBS treatment window — initiation within 8 weeks of symptom onset
    GBS treatment timingInitial treatment with immune globulin must occur within eight (8) weeks of symptom onset.
    Course durationTreatment is limited to one course, typically no more than 5 days (acute therapy).
    Concomitant therapy exclusionIndividual must not be on concomitant plasmapheresis when receiving IVIG for GBS per policy criteria.
    inv-70: ITP platelet threshold — platelet count threshold for ITP
    ITP platelet thresholdPlatelet count less than 30,000 mcL is a qualifying criterion for IVIG use in immune thrombocytopenia (ITP).
    Bleeding criterionActive bleeding (e.g., hematuria, petechiae, GI bleeding, gingival bleeding) is an alternative trigger for treatment regardless of platelet count.
    Reference guidelineThreshold aligned with ASH 2019 guidance cited in policy.
    inv-72: Azathioprine/mycophenolate trial duration for myasthenia gravis — at least 12 months
    Azathioprine/mycophenolate trial durationAt least a twelve (12) month trial of azathioprine or mycophenolate is required before considering continued IVIG for myasthenia gravis.
    Purpose of trialUsed to allow steroid-sparing and assess adequacy of immunosuppression prior to long‑term IVIG maintenance consideration.
    Continuation criteria linkageContinued IVIG requires objective clinical improvement and demonstrated ongoing need after immunosuppressant trial.
    inv-73: Alternate immunosuppressant trial duration for myasthenia gravis — at least 2 months for several agents
    Alternate immunosuppressant minimum durationAt least two (2) months trial required for cyclosporine, cyclophosphamide, tacrolimus, or methotrexate in myasthenia gravis prior to IVIG continuation consideration.
    Context of useThese shorter trials apply when azathioprine/mycophenolate are not used or appropriate; documentation of inadequate response or intolerance is required.
    Continuation requirementContinued IVIG use also requires clinically significant and objective improvement on exam.
    inv-74: Hypogammaglobulinemia threshold for CMV pneumonia — IgG < 500 mg/dL
    CMV pneumonia hypogammaglobulinemia thresholdIgG less than 500 mg/dL is specified as the threshold for considering immune globulin treatment for cancer-related CMV pneumonia.
    Indication contextApplies in cancer-related CMV pneumonia per NCCN 2A guidance as cited in policy.
    Approval durationApproval duration for this indication noted as 6 months in the policy's infectious indications section.
    inv-75: CIDP dosing frequency and amount — dosing example (1000 mg/kg q3 weeks, possible loading to 2000 mg/kg)
    CIDP typical dosing example1000 mg/kg (may be divided over two days) administered as frequently as every 3 weeks is the listed CIDP dosing regimen; initial loading doses up to 2000 mg/kg may be approved as an override for initiation.
    Loading dose optionLoading/initiation dosing may be up to 2000 mg/kg divided over 2–5 days when clinically indicated for CIDP initiation.
    Quantity limit authorityDosing limits and override criteria are provided in the Intravenous Immunoglobulin Quantity Limits section of the policy.
    inv-76: IgG threshold for hypogammaglobulinemia — < 400 mg/dL (policy historical threshold)
    Historical hypogammaglobulinemia thresholdPolicy history documents a historical definition of hypogammaglobulinemia as IgG < 400 mg/dL per cited guidelines.
    Guideline originThe <400 mg/dL threshold was added in the 11/16/2018 annual review referencing guideline updates.
    Current vs historical noteWhile historical threshold <400 mg/dL is recorded in document history, condition-specific thresholds (e.g., <500 mg/dL for CLL) are used elsewhere in the policy.
    inv-77: Effective date groups (Commercial) — 02/01/2025; 05/01/2026
    Commercial effective-date groupsCommercial preferred/non-preferred lists have effective-date groups: 02/01/2025 and 05/01/2026.
    Implication for prior authorizationProduct preference status (preferred vs non-preferred) depends on the effective-date group and may affect step therapy/prior authorization requirements.
    Examples notedGammagard Liquid ERC was added to Commercial preferred list effective 05/01/2026; Qivigy added to Commercial non-preferred list effective 05/01/2026.
    inv-78: Effective date groups (Medicare) — 04/01/2025; 05/01/2026
    Medicare effective-date groupsMedicare preferred/non-preferred lists have effective-date groups: 04/01/2025 and 05/01/2026.
    Product preference changesMedicare lists show changes between 04/01/2025 and 05/01/2026 (e.g., addition of Xembify to 05/01/2026 preferred group for some routes).
    Step-through noteSubcutaneous preferred products require stepping through an intravenous preferred product as noted in policy notes for both Commercial and Medicare lists.

    Prior Authorization, Documentation, and Step Therapy

    Prior Authorization

    Prior authorization required for medical-benefit IG requests

    Prior authorization is required whenever a requested immunoglobulin product is reviewed under the member's medical benefit; the request will be evaluated against this policy's clinical criteria to determine medical necessity.

    Prior Authorization

    Include indication-specific clinical documentation with PA

    Submit a prior authorization request that includes clinical documentation demonstrating the specific indication and that the member meets the policy's listed clinical and laboratory criteria (e.g., diagnosis, IgG thresholds, prior therapy trials, timing of symptoms where required).

    Prior Authorization

    PA approvals have indication-specific durations

    Prior authorization approvals are issued for indication-specific durations — initial and continuation approval periods vary by diagnosis (examples: initial CIDP/CIDP-like trials up to 12 weeks with 1-year continuation; GBS limited to one 5‑day course).

    Step Therapy

    Step therapy and PA required for non-preferred IG agents

    Prior authorization is required and subject to step-therapy rules: requests for non-preferred IVIG or SCIG agents must document trials of preferred agents or meet specified clinical rationales for override (for example, intolerance, severe IgA deficiency, or other listed reasons).

    • Non-preferred IVIG: documentation of trial and inadequate response or intolerance to two preferred IVIG agents, or acceptable clinical rationale (e.g., severe IgA deficiency <7 mg/dL).
    • Non-preferred SCIG-only: documentation of trials of two preferred SCIG agents or justification per policy (e.g., difficult venous access with rationale).
    Billing Rule

    HCPCS codes for IG products are listed in the policy

    The policy lists HCPCS codes for immune globulin products; use the listed HCPCS/J-codes or designated unclassified codes exactly as shown when requesting and billing IG products.

    Billing Rule

    Submit claims/PA using the listed J‑codes

    Claims and prior authorization requests should use the product-specific HCPCS J-codes shown in the policy (for example J1558, J1559, J1561, J1566, J1568, J1569, J1572, J1575) that correspond to the exact product and billing unit.

    Note

    HCPCS code descriptors for PA and billing reference

    This policy section provides HCPCS descriptors that are relevant for PA and billing (for example J1559, J1561, J1566, J1568, J1569, J1572, J1575, J1576) and should be referenced when completing authorization/billing workflows.

    Billing Rule

    Use listed HCPCS codes that identify IG products

    Use the HCPCS codes listed (examples: J1561, J1566, J1568, J1569, J1572, J1575, J1576, J1599) on claims and when identifying the administered immune globulin product for benefit adjudication.

    Billing Rule

    Use exact HCPCS codes (including J3590 when specified) on claims

    Submit claims using the exact HCPCS codes corresponding to the administered product (examples listed: J1566, J1568, J1569, J1572, J1575, J1576, J1599; J3590 when specified as Qivigy) to ensure correct claim processing and benefit assignment.

    Prior Authorization

    Code-based PA and claims: include product and home‑infusion codes

    Prior authorization requests and claims should use the specific HCPCS codes listed (for example J1566, J1568, J1569, J1572, J1575, J1576, J1599) and include Q2052 when home infusion supplies/services are applicable.

    Billing Rule

    Use these HCPCS/J‑codes for claims and PA

    Use the listed HCPCS/J-codes exactly as specified for immune globulin products and for associated home administration supplies when submitting prior authorization requests and claims.

    • Include Q2052 for home infusion supplies when applicable.
    Prior Authorization

    Reference exact HCPCS/J/Q/S codes in PA (including S9338 for home infusion)

    Reference the exact HCPCS/J/Q/S code requested (for IVIG/SCIG or home infusion) in prior authorization submissions; S9338 is used for home infusion per diem services where applicable.

    • Include S9338 for home infusion service per diem when applicable.
    • Specify the exact J- or Q-code for the IG product being requested.
    Prior Authorization

    PA and coding must match listed J/Q/S codes

    Prior authorization and accurate coding must use the listed J-codes, Q2052 and S9338 (as applicable) to ensure correct benefit adjudication and assignment of services to the medical benefit.

    Note

    PA decisions reflect step‑therapy and coding updates

    Prior authorization decisions incorporate step therapy and coding updates; providers should account for recent code additions/changes in the policy when requesting non‑preferred agents or home infusion services.

    Prior Authorization

    PA may depend on product preference (preferred vs non‑preferred)

    Anthem classifies immunoglobulin products as preferred or non‑preferred by benefit and effective date; prior authorization requirements (including step‑therapy trials and overrides) may vary depending on the product's preference status.

    • Check the Commercial or Medicare preferred/non‑preferred lists for the applicable effective date before requesting a non‑preferred agent.
    Note

    Step‑therapy expectations: reserve IG after alternative therapy trials

    For many autoimmune and inflammatory indications, IG is reserved for patients who have had inadequate response, intolerance, or contraindication to standard alternatives; document prior therapies and failures in the PA submission.

    Step Therapy

    Preferred‑product requirement may apply despite meeting clinical criteria

    Plans may require use of a preferred immunoglobulin agent(s) even when clinical criteria are met; obtain authorization for non‑preferred products only after meeting step‑therapy/override requirements.

    Documentation Required

    Required documentation to support non‑preferred IG requests

    When approval is sought for a non‑preferred IVIG or SCIG agent, include documentation showing trials and inadequate response/intolerance to two preferred agents or allowed clinical reasons (for example severe IgA deficiency <7 mg/dL, hypersensitivity, hemolysis or renal dysfunction) to support an override.

    • List dates and outcomes of preferred-agent trials and provide objective evidence of intolerance or inadequate response.
    Documentation Required

    Include electrodiagnostic and objective measures for neurologic indications

    Electrodiagnostic test results (e.g., NCS, RNS, SFEMG) and other objective measures used to confirm neurologic diagnoses such as CIDP should be supplied with authorization requests when applicable.

    • For CIDP, include electrodiagnostic findings consistent with EFNS/PNS or AAN parameters and documentation of symptom duration (>2 months).
    Documentation Required

    Required clinical and laboratory documentation for PA

    Providers must document diagnosis, relevant laboratory results (for example pre‑treatment total serum IgG, IgG subclass levels, CD3+ T cell count when indicated), history of infections or vaccine response, and prior therapy trials as applicable in the PA submission.

    • Include total serum IgG and relevant subclass values when indicated.
    • For transplant/HCT and some oncology indications, include IgG thresholds (e.g., IgG <400–500 mg/dL where specified).
    Documentation Required

    Document objective clinical response for continuation PA

    Continuation requests must demonstrate objective clinical improvement or ongoing functional impairment as specified per condition (for example: clinically significant exam improvement for CIDP, MMN, MG; stability on current dose or worsening with dose decrease).

    Documentation Required

    Non‑preferred IG requests: detail preferred‑agent trials or clinical rationale

    Documentation for non‑preferred IG requests must show trials and inadequate response or intolerance to the specified preferred agents (commonly two), or provide a clinical rationale for why preferred agents are unacceptable.

    • Examples of acceptable rationale: severe IgA deficiency (<7 mg/dL), IgA antibodies, hypersensitivity to excipients, clinically significant hemolysis or renal dysfunction with preferred agents.
    Billing Rule

    Specify exact HCPCS J‑code and unit size on PA and claims

    Use the exact HCPCS J-code that corresponds to the immune globulin product and billing unit when submitting PA requests and claims (examples provided in the policy: J1558 for Xembify 100 mg, J1559 for Hizentra 100 mg, and multiple 500 mg IV codes).

    Billing Rule

    Include product HCPCS and home‑infusion supply/service codes (Q2052, S9338)

    Include HCPCS code(s) for the IG product and Q2052 for home infusion supplies when applicable; when home infusion services are provided, reference S9338 for home infusion per‑diem services.

    • Examples: J1568, J1569, J1572, J1575, J1576, J1599 and Q2052 for supplies; S9338 for home infusion per diem.
    Denial Risk

    Denial risk: failure to meet clinical or laboratory criteria

    PA approvals may be denied if requests do not meet the policy's clinical criteria, laboratory thresholds (e.g., required IgG values), documented prior‑therapy requirements, or lack required objective documentation.

    • Examples of denial triggers: missing diagnostic criteria, absent required IgG thresholds, no documented trials of required alternative therapies, or absence of objective response data for continuation requests.
    Denial Risk

    Denial risk: non‑approved indications

    Requests for non‑approved indications listed in the policy (for example Alzheimer’s disease, immune optic neuropathy except MOG‑related NMOSD, multiple sclerosis, PANDAS) are not approvable per the policy.

    Denial Risk

    Denial risk for non‑preferred IVIG without required trials

    Requests for non‑preferred IVIG agents risk denial unless documentation shows trials and inadequate response or intolerance to two preferred IVIG agents or other allowed clinical reasons as specified in policy.

    Denial Risk

    Denial risk for non‑preferred SCIG without required trials or justification

    Requests for non‑preferred SCIG‑only agents risk denial if documentation does not demonstrate trials of two preferred SCIG agents or acceptable clinical justification (examples: severe IgA deficiency, hypersensitivity, difficult venous access with rationale).

    Denial Risk

    Coding mismatch or use of unclassified codes may trigger denial

    Using an unlisted or incorrect HCPCS/J‑code (for example using J3590 or a NOC code when a product‑specific J‑code exists) may delay processing or trigger claim denial; ensure the product‑specific code is used when available.

    • Qivigy may be reported as J1599 or, when specified, J3590/C9399 per the policy — confirm the correct code mapping in the policy when requesting/billing.
    Denial Risk

    Coding errors or outdated mappings risk claim denial

    Missing or incorrect HCPCS/J‑code specification (for example using an unlisted code when a product‑specific J‑code exists) may trigger processing denials; verify codes against the current policy list and recent coding updates.

    Note

    Verify current step‑therapy and code updates before PA submission

    Step‑therapy table updates and coding changes have occurred periodically; providers should confirm the current preferred/non‑preferred product lists and code mappings for the member's benefit and the policy effective dates before submitting PA requests.

    • Document history shows multiple recent updates (e.g., additions of J1572, J1599 and removal/changes for Yimmugo/Gammagard ERC).
    Note

    Background and Scope

    Immunoglobulin preparations are plasma‑derived products used intravenously (IVIG) or subcutaneously (SCIG) to replace deficient antibodies, treat certain infections, and provide anti‑inflammatory and immunomodulatory effects. They are standard therapy for primary humoral immunodeficiencies and have multiple other FDA‑approved and well‑recognized off‑label uses across infectious, transplant, autoimmune, hematologic, and neurologic conditions. Product selection should consider route (IV vs SC), product properties, and the clinical indication being treated.

    Definitions and Key Terms

    inv-141: PI — Primary (Humoral) Immunodeficiency definition and examples
    DefinitionPrimary (Humoral) Immunodeficiency (PI): includes conditions such as Common Variable Immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, and Severe Combined Immunodeficiencies.
    Clinical applicationPI is an established indication for immunoglobulin replacement when laboratory and clinical criteria (e.g., low IgG and recurrent infections) are met.
    Reference guidelineAAAI/ACAAI 2015 guidance referenced for primary humoral immunodeficiency criteria in policy.
    inv-142: IV / SC — Route definitions (IV and SC)
    IV definitionIV = Intravenous route for immunoglobulin administration (IVIG).
    SC definitionSC = Subcutaneous route for immunoglobulin administration (SCIG).
    Policy notePolicy lists product properties that indicate route (IV or SC) for each agent to guide selection when route-specific factors matter.
    inv-143: At-risk for thrombosis/renal dysfunction — Risk factors defined
    Risk-factor examplesAt-risk for thrombosis or renal dysfunction includes advanced age, prolonged immobilization, hypercoagulable conditions, prior venous/arterial thrombosis, estrogen use, indwelling vascular catheters, hyperviscosity, preexisting renal insufficiency, diabetes, volume depletion, sepsis, paraproteinemia, or concurrent nephrotoxic drugs.
    Administration cautionIn at-risk patients, administer IG at the minimum dose and infusion rate practicable, ensure adequate hydration, and monitor for thrombosis and renal dysfunction.
    Product-specific riskRenal dysfunction and acute renal failure occur more commonly with IGIV products containing sucrose; consider product properties when selecting agent for at-risk patients.
    inv-144: Guillain-Barré Syndrome (GBS) — Definition and note on treatment timing
    GBS definitionGuillain-Barré Syndrome (GBS) is an acute demyelinating polyneuropathy characterized by progressive limb weakness and absent or depressed tendon reflexes.
    Treatment timing noteInitial IVIG treatment should occur within 8 weeks of symptom onset and is limited to one course (typically up to 5 days).
    Concomitant therapyIVIG should not be administered concurrently with plasmapheresis for GBS per policy criteria.
    inv-145: MOG-related NMOSD — Definition and seropositivity criteria
    MOG-related NMOSD definitionMyelin oligodendrocyte glycoprotein (MOG)-related neuromyelitis optica spectrum disorder: seropositivity for MOG antibodies and seronegativity for AQP4 antibodies.
    Induction useIVIG may be used as induction for an acute episode after inadequate response/intolerance/contraindication to corticosteroids or for relapse after maintenance therapy.
    Continuation criteriaContinued maintenance use requires evidence of clinical response such as reduction in relapse frequency.
    inv-146: Product properties — Policy lists selected properties for each IG product (route, osmolality, sodium, IgA content)
    Product properties listedPolicy lists selected properties for each IG product including route (IV or SC), osmolality (mOsm/kg), sodium content, IgA content (µg/mL), and stabilizer/regulator.
    Purpose of propertiesThese properties inform product selection for patients with specific clinical needs (e.g., low IgA requirement, renal risk, sodium restriction).
    Examples providedExamples in policy include osmolality ranges, IgA concentrations, and stabilizers for agents such as Asceniv, Cutaquig, Gamunex-C, HyQvia, Octagam, Panzyga, and others.
    inv-147: Severe IgA deficiency — Definition (IgA <7 mg/dL or anti-IgA antibodies) and related product selection notes
    Severe IgA deficiency definitionSevere IgA deficiency defined as IgA < 7 mg/dL or IgA deficiency with antibodies against IgA.
    Implication for product selectionSuch patients may require IG products with very low IgA content; documentation supports use of non‑preferred agent if preferred products are unsuitable.
    Policy exampleSevere IgA deficiency is listed among clinical conditions that justify selection of a non-preferred SCIG/IVIG agent with specific properties.
    inv-148: HCPCS J-code — Definition of J-code usage for billing drugs/biologics
    HCPCS J-code definitionA five-character alphanumeric code (J####) used to bill drugs and biologics administered in outpatient settings; used here to identify specific immune globulin products and billing units.
    Use in claims/prior authorizationProviders must submit the exact HCPCS J-code corresponding to the product and unit (e.g., 100 mg or 500 mg) for claims and prior authorization requests.
    Unclassified code noteWhen product-specific J-code is not available or product is specified as Qivigy, unclassified codes (e.g., J3590, C9399) may be referenced per policy guidance.
    inv-149: HCPCS immune globulin codes — HCPCS J-codes with formulation and unit-size descriptors
    HCPCS immune globulin codes listingPolicy provides HCPCS J-codes mapping to immune globulin products with formulation and unit-size descriptors (examples: J1558/J1559 100 mg SC units; J1561/J1566/J1568/J1569 etc. 500 mg IV units).
    Unit-of-measure examplesMany IV formulations are billed per 500 mg units; subcutaneous and hyaluronidase-containing products are commonly billed per 100 mg units.
    Coding cautionUse the specific J-code for the administered product; misuse of unclassified codes (J3590/C9399) when product-specific codes exist may trigger coding risk.
    inv-150: J1575 (HyQvia) — Specific note that J1575 is immune globulin combined with hyaluronidase (100 mg IG unit)
    HyQvia (J1575) noteJ1575 represents immune globulin combined with hyaluronidase (HyQvia) and is listed with a 100 mg immune globulin unit for billing.
    Route and unitHyQvia is a subcutaneous/hyaluronidase‑facilitated product billed per 100 mg IG unit as indicated by policy HCPCS mappings.
    Implication for claimsInclude J1575 on claims for HyQvia and document product name and unit when seeking prior authorization or reimbursement.
    inv-151: IVIG / immune globulin (intravenous) — IVIG product listing and 500 mg billing unit note
    IVIG product billing unitMultiple intravenous immune globulin products are identified by J-codes billed per 500 mg unit (common billing unit for many IV formulations).
    Product examplesExamples include Carimune NF, Gammagard S/D, Octagam, Gammagard Liquid, Flebogamma, Panzyga, Privigen, and others mapped to specific J-codes.
    Claim documentationWhen billing, providers should use the exact J-code that corresponds to the IVIG product and 500 mg unit descriptor to ensure correct adjudication.
    inv-152: Q2052 — Home infusion services/supplies code definition
    Q2052 definitionQ2052 = Services, supplies and accessories used in the home for the administration of intravenous immune globulin (IVIG).
    When to useInclude Q2052 on claims when home infusion supplies/services are part of the IVIG administration episode.
    Related codesPair Q2052 with the appropriate J-code for the IG product and consider S9338 for home infusion per diem services where applicable.
    inv-153: S9338 — Home infusion therapy service code definition and scope
    S9338 definitionS9338 = Home infusion therapy; immunotherapy, administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment, per diem.
    Use caseUse S9338 for reporting home infusion therapy services associated with IVIG when per‑diem home infusion support is provided.
    Coding combinationReport S9338 alongside the IG product J-code and Q2052 as applicable for comprehensive home infusion billing.
    inv-154: J-codes / Q2052 / J3590 — Reference to HCPCS/J/Q/S codes used for immune globulin reporting
    Codes referenced togetherPolicy references HCPCS product-specific J-codes, Q2052 for home supplies, and J3590 or C9399 as unclassified biologic codes when specified (e.g., Qivigy).
    Billing precisionProviders should document and submit the exact HCPCS/J/Q/S code and product name as requested for prior authorization and claims to avoid coding-related denials.
    Unclassified code cautionJ3590 or C9399 may be used when products are specified as Qivigy or when no product-specific code exists; ensure documentation specifies product mapping.
    inv-155: S9338 — Home infusion therapy code reiterated
    S9338 reiteratedS9338 is the HCPCS code for home infusion therapy and is included in the policy's covered codes for IVIG home administration.
    Documentation guidanceWhen billing S9338, include supporting documentation of home infusion services and the associated IG product J-code.
    Combination useS9338 is listed alongside J1568/J1569/J1572/J1575/J1576/J1599/J3590 and Q2052 in the HCPCS code tables for home infusion scenarios.
    inv-156: J1568-J1599 — Range of HCPCS J-codes representing specific IVIG products billed per 500 mg
    J1568-J1599 rangePolicy lists a range of HCPCS J-codes (J1568–J1599) representing specific IVIG products billed per 500 mg (examples: Octagam J1568, Gammagard Liquid J1569, Panzyga J1576, J1599 for NOS entries).
    Use of J1599J1599 is used for IVIG not otherwise specified and may be mapped to products like Qivigy when indicated.
    Claiming practiceSelect the exact product-specific J-code within this range whenever available to minimize use of unclassified codes.
    inv-157: J3590 / Q2052 — Unclassified biologic or Q-code when specified as particular products (e.g., Qivigy)
    J3590 / Q2052 useJ3590 (unclassified biologic) or Q2052 may be used when Qivigy or other products are specified and no product‑specific J-code is appropriate; ensure product name is documented.
    Documentation requiredWhen using J3590/Q2052, indicate the specific product (e.g., Qivigy) in documentation to support coding choice.
    Coding riskUse of unclassified codes when product-specific codes exist can lead to processing issues; review document history for code additions/removals affecting mapping.
    inv-158: Hypogammaglobulinemia — Historical policy definition (IgG <400 mg/dL)
    Historical hypogammaglobulinemia definitionDocument history records that the policy historically defined hypogammaglobulinemia as IgG < 400 mg/dL per cited guidelines (added 11/16/2018).
    Guideline linkageThis historical threshold was added referencing guideline updates at the time (document history entry).
    Current usage noteSome condition-specific sections of the policy use different numeric thresholds (e.g., <500 mg/dL for CLL), so apply the threshold relevant to the specific indication.
    inv-159: Preferred Agents — Definition of payer 'preferred' products
    Preferred Agents definitionPreferred Agents are products the payer lists as preferred for a given benefit and effective date; lists are published in the policy (Commercial and Medicare groups).
    Step therapy impactPreferred status affects step therapy requirements; non-preferred agents generally require trials of preferred agents or clinical justification.
    Effective-date dependenceProduct classification as preferred may change by effective-date group (e.g., updates effective 02/01/2025 and 05/01/2026 for Commercial).
    inv-160: Non-Preferred Agents — Definition of payer 'non-preferred' products
    Non-Preferred Agents definitionNon-Preferred Agents are products the payer lists as non-preferred for a given benefit and effective date; requests require documentation of trials of preferred agents or clinical rationale per step therapy rules.
    Requirements for approvalApproval of non-preferred IVIG typically requires documentation of trial and inadequate response or intolerance to two preferred IVIG agents, or demonstration that preferred agents are clinically unacceptable.
    SCIG-specific noteFor non-preferred SCIG-only agents, documentation of trials of two preferred SCIG agents or other justifications (e.g., severe IgA deficiency, hypersensitivity) is required.

    Document History and Policy Changes

    2026-03-26Step therapy & coding updateLatest

    Step therapy table updates; removed Yimmugo from HCPCS NOC C9399 and J3590 effective 2026-03-31, added J1553 effective 2026-04-01, added J1599 for Qivigy, and moved Gammagard Liquid ERC from HCPCS NOC C9399/J3590 to J1569; reflects clinical and coding changes through March 26, 2026.

    2026-02-01Step therapy update

    Step therapy table updates recorded on 2026-02-01 (policy history lists iterative step therapy modifications in early 2026).

    2025-11-14Annual clinical criteria revision

    Annual review updated clinical criteria for CIDP, added indications for immune checkpoint inhibitor–related toxicities and warm-type autoimmune hemolytic anemia, and added agents Gammagard Liquid ERC and Qivigy to clinical criteria and step therapy properties; coding edits also applied.

    2025-05-16Step therapy and coding review

    Select review updated step therapy criteria to remove grandfathering allowance and add overrides for non-preferred agents; coding description for HCPCS J1561 was updated.

    2025-01-02Coding update

    Coding update added HCPCS J1572 (noting subsequent removal effective 1/1/2026 per later history).

    2024-11-15Annual clinical update

    Annual review updated criteria for multiple myeloma and applied step therapy updates; coding reviewed with addition of HCPCS J1552 effective 1/1/2025 and deletion of HCPCS J1599 for Alyglo.

    2026-03-26Step therapy & coding updateLatest

    Step therapy table updates through March 26, 2026, including removal of Yimmugo from HCPCS NOC C9399 and J3590 effective 2026-03-31 and addition of J1553 effective 2026-04-01, plus addition of J1599 for Qivigy; documents repeated step therapy table changes reflected in provider step rules and product lists.

    2026-02-01Step therapy update

    Step therapy table updates noted on 2026-02-01 as part of ongoing adjustments to preferred/non-preferred product policies.

    2025-05-16Step therapy policy change

    Certain intramuscular immunoglobulin HCPCS entries (for example J1460 and J1560 referenced historically) were removed from this policy and are now managed under a different policy (CC‑0039). See the document history for coding and step therapy table updates that note product and code reassignments.

    The document history records prior definitions and updates related to hypogammaglobulinemia. Historically the policy defined hypogammaglobulinemia (for some indications) as total IgG < 400 mg/dL per cited guideline updates; see the revision history entries for when thresholds and wording were changed.

    Commercial product preference lists have been updated with effective dates noted in the document history. The policy lists Commercial preferred/non‑preferred agents with effective groups including 02/01/2025 and 05/01/2026; see the preference tables and history for the exact product assignments and effective dates.

    Medicare product preference lists were likewise updated and effective dates are documented in the policy history. Preference groups include changes effective 04/01/2025 and 05/01/2026; consult the Medicare preference table in the policy for specific product classifications by date.

    Select review on 2025-05-16 updated step therapy criteria to remove grandfathering allowance and added specific overrides for non-preferred agents and existing users.

    2024-10-23Step therapy update

    Step therapy table updates recorded on 2024-10-23 as part of iterative modifications to the step therapy table.

    2024-08-16Agent addition and coding review

    Select review added new agent Yimmugo to the document and added HCPCS J3590 mapping for Yimmugo; additional coding adjustments and removals of intramuscular codes were made.